This review highlights the evolution of stent technology from durable polymer DES to biodegradable polymer and polymer-free DES, paving the way for fully bioresorbable scaffolds to improve long-term vascular healing.
Answers are grounded in this paper and cite their sources.
May inform stent choice in thrombosis-prone patients; leaves open confirmation via large randomized trials.
Drug eluting stents and particularly the fully bioresorbable drug-eluting scaffolds herald a new era in percutaneous treatment of coronary artery disease. There has been tremendous progress in drug eluting stents with fully biodegradable coating polymers and polymer-free devices with reservoir technology planting the anti-proliferative drug. Despite significant decreases in in-stent restenosis rates with drug eluting stents, limitations still remain before we are able to develop fully bioresorbable scaffolds. Enhanced mechanical flexibility that provides superior conformability to the vessel wall, resumption of the vasoreactivity in the follow-up period and improving visualization on non-invasive imaging modalities are some of the supremacies of the fully bioresorbable scaffolds. In this review, we aim to give a general view on the latest developments in metallic drug eluting stents and fully bioresorbable scaffolds.
No takes yet. Share an insight, caveat, or question.
Tenekecioğlu et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: